Compare GLDG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDG | CRBU |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 167.6M |
| IPO Year | 2012 | 2021 |
| Metric | GLDG | CRBU |
|---|---|---|
| Price | $0.87 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.75 | ★ $10.75 |
| AVG Volume (30 Days) | 1.9M | ★ 1.9M |
| Earning Date | 04-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.22 |
| 52 Week High | $2.27 | $3.53 |
| Indicator | GLDG | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 36.16 |
| Support Level | $0.85 | $1.39 |
| Resistance Level | $1.07 | $1.73 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 5.74 | 14.66 |
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. Its principal projects are the La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; the Sao Jorge Gold Project, located in Brazil; and its interest in the Whistler Gold-Copper Project, located in Alaska, United States. Additionally, the company has several other projects in its portfolio, such as the Yellowknife Gold Project, Cachoeira Gold Project, Surubim Gold Project, Yarumalito Gold Project, Rea Uranium Project, etc. The firm has two operating segments, with U.S. GoldMining as one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.